Lupin ESG rating falls to 70 in FY26 on lower social, governance scores

scanx
Reviewed by
Riya DScanX News Team
Key Highlights
  • Lupin Limited's NSE Sustainability ESG rating declined to 70 in FY26 from 71 in FY25
  • The overall score drop is driven by a one-point decline in both Social and Governance scores
  • NSE Sustainability independently assessed the company using publicly available information
  • Disclosure made under Regulation 30 of SEBI LODR Regulations, 2015
powered bylight_fuzz_icon
53615235

*this image is generated using AI for illustrative purposes only.

Lupin Limited received an Environmental, Social and Governance (ESG) rating of 70 for FY26 from NSE Sustainability Ratings and Analytics Limited. This marks a marginal decline from the rating of 71 assigned in the previous fiscal year.

The one-point drop in the overall score is attributed to a decrease in both the Social and Governance sub-scores by one point each. The company disclosed this development pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Rating methodology and independence

NSE Sustainability independently prepared the report using publicly available information about the company. Lupin did not engage NSE Sustainability for this specific ESG rating exercise, ensuring the assessment remained an independent evaluation based on public disclosures.

Metric FY26 Rating FY25 Rating Change
Overall ESG Score 70 71 -1
Social Score Impact Lower Higher -1 point
Governance Score Impact Lower Higher -1 point

What the Numbers Show

The data indicates that the decline in Lupin's overall ESG standing was not driven by environmental factors, but specifically by a uniform reduction in Social and Governance metrics. The equal one-point deduction in both categories suggests a balanced erosion in non-environmental pillars rather than a singular compliance or social issue.

Historical Stock Returns for Lupin

1 Day5 Days1 Month6 Months1 Year5 Years
-0.97%+1.28%-4.92%-16.13%+1.09%0.0%

How might the decline in Social and Governance sub-scores influence Lupin's eligibility for ESG-focused institutional investment funds?

What specific governance reforms or social initiatives is Lupin planning to implement to reverse the downward trend in its FY27 ESG rating?

Could the independent nature of NSE's assessment trigger increased scrutiny from regulators regarding Lupin's public disclosure practices?

Lupin gets US FDA approval for Phytonadione injectable emulsion

scanx
Reviewed by
Naman SScanX News Team
Key Highlights
  • Lupin secured US FDA approval for Phytonadione Injectable Emulsion USP
  • The product is a 1 mg/0.5 mL single-dose prefilled syringe
  • The target market has estimated annual sales of $52.3 million in the U.S.
  • Approval confirms bioequivalence to International Medication Systems' RLD
powered bylight_fuzz_icon
53019564

*this image is generated using AI for illustrative purposes only.

Lupin has received approval from the US Food and Drug Administration (US FDA) for Phytonadione Injectable Emulsion USP, 1 MG/0.5 ML Single-dose Prefilled Syringe.

Regulatory approval details

The US FDA clearance covers Phytonadione Injectable Emulsion in a pre-filled syringe format at a concentration of 1 MG/0.5 ML. The approval confirms the product is bioequivalent to the reference listed drug (RLD), Phytonadione Injectable Emulsion, 1 mg/0.5 mL, of International Medication Systems, Limited. It is indicated for the treatment and prophylaxis of hypoprothrombinemia (low blood clotting) and vitamin K-deficiency.

The following table summarises the key details of the approved product.

Parameter Details
Product name Phytonadione Injectable Emulsion USP
Strength 1 MG/0.5 ML
Dosage form Pre-filled Syringe
Regulatory authority US FDA
Company Lupin

This approval adds an injectable emulsion product to Lupin's US portfolio, reflecting the company's continued engagement with the US regulatory process for pharmaceutical products.

Market opportunity

Phytonadione Injectable Emulsion had estimated annual sales of $52.3 million in the U.S., according to IQVIA data for the moving annual total (MAT) ending August 2026. This figure highlights the commercial potential of the newly approved generic entry into the US market.

Historical Stock Returns for Lupin

1 Day5 Days1 Month6 Months1 Year5 Years
-0.97%+1.28%-4.92%-16.13%+1.09%0.0%
Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

How will Lupin's pricing strategy for the Phytonadione generic impact the existing market share of International Medication Systems?

What is the expected timeline for Lupin to launch this product and capture a significant portion of the $52.3 million annual market?

Are there other competitors currently awaiting FDA approval for similar Phytonadione injectable generics that could intensify price competition?

More News on Lupin

1 Year Returns:+1.09%